SOLVx therapeutics vaccine – Activate T-cell immunity using broad surveillance epitope strategy against mutant strains SARS-COV2

Highly mutable Coronavirus-19 continuously reconstructs its genome and renders prophylactic vaccines ineffective. The objective of the present study was to demonstrate the anti-viral efficacy and safety of the SOLVx therapeutics vaccine. The peptides were designed with Neo7Logix R&D and synthesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Md Shamsuddin Sultan, Catanzaro, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149046/
https://www.ncbi.nlm.nih.gov/pubmed/35653885
http://dx.doi.org/10.1016/j.biopha.2022.113212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149046/
https://www.ncbi.nlm.nih.gov/pubmed/35653885
http://dx.doi.org/10.1016/j.biopha.2022.113212

Ejemplares similares